Onconetix Files 10-K, Confirms Compliance as Smaller Reporting Company
Ticker: ONCO · Form: 10-K · Filed: Jun 2, 2025 · CIK: 1782107
Sentiment: neutral
Topics: Pharmaceuticals, 10-K Filing, SEC Compliance, Smaller Reporting Company, Biotech, Nasdaq, Corporate Governance
Related Tickers: ONCO
TL;DR
**ONCO's 10-K confirms regulatory compliance, but without financials, it's a holding pattern for investors.**
AI Summary
Onconetix, Inc. reported its 10-K for the fiscal year ended December 31, 2024, indicating its status as a non-accelerated filer and a smaller reporting company. The company, formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc., operates in the pharmaceutical preparations industry. Its common stock, with a $0.00001 par value, is traded on The Nasdaq Stock Market LLC under the ticker ONCO. The filing confirms that Onconetix has filed all required reports under the Securities Exchange Act of 1934 during the preceding 12 months and has submitted every Interactive Data File pursuant to Rule 405 of Regulation S-T. The company's business address is 201 E. Fifth Street, Suite 1900, Cincinnati, OH 45202, and its telephone number is (513) 620-4101. Specific revenue and net income figures were not provided in the excerpt, but the company's operational compliance with SEC regulations was highlighted.
Why It Matters
This filing confirms Onconetix's continued compliance with SEC reporting requirements, which is crucial for investor confidence and market transparency. As a smaller reporting company, ONCO faces different regulatory burdens and investor scrutiny compared to larger pharmaceutical firms, impacting its competitive positioning. Employees and customers can infer a stable, compliant operational environment, though the lack of financial specifics in this excerpt limits deeper analysis. The broader market will note ONCO's adherence to filing standards, a baseline expectation for any publicly traded entity.
Risk Assessment
Risk Level: medium — The risk level is medium because while the company confirms compliance with SEC filings, the provided excerpt lacks crucial financial data such as revenue, net income, or cash flow. This absence prevents a comprehensive assessment of operational and financial health, leaving investors with incomplete information to evaluate the company's intrinsic value and future prospects.
Analyst Insight
Investors should await the full financial statements within the 10-K to assess Onconetix's performance and financial health. Without specific revenue, net income, or balance sheet figures, any investment decision would be speculative. Focus on the company's drug pipeline progress and cash burn once the complete filing is available.
Key Numbers
- $0.00001 — Common Stock Par Value (Indicates the nominal value per share of Onconetix's common stock.)
- 20241231 — Fiscal Year End Date (The period covered by this 10-K filing for Onconetix, Inc.)
- 001-41294 — Commission File Number (Unique identifier for Onconetix's filings with the SEC.)
- 20250602 — Filed As Of Date (The date Onconetix's 10-K was officially filed with the SEC.)
Key Players & Entities
- Onconetix, Inc. (company) — registrant for 10-K filing
- ONCO (company) — trading symbol on Nasdaq
- The Nasdaq Stock Market LLC (regulator) — exchange where ONCO common stock is registered
- Blue Water Biotech, Inc. (company) — former company name of Onconetix, Inc.
- Blue Water Vaccines Inc. (company) — former company name of Onconetix, Inc.
- SEC (regulator) — Securities and Exchange Commission
- December 31, 2024 (date) — fiscal year end for the 10-K
- 201 E. Fifth Street, Suite 1900, Cincinnati, OH 45202 (company) — business address of Onconetix, Inc.
- $0.00001 (dollar_amount) — par value of common stock
- 513-620-4101 (person) — business phone number of Onconetix, Inc.
FAQ
What is Onconetix, Inc.'s ticker symbol and where is it traded?
Onconetix, Inc.'s ticker symbol is ONCO, and its common stock is traded on The Nasdaq Stock Market LLC.
When did Onconetix, Inc. file its 10-K for the fiscal year 2024?
Onconetix, Inc. filed its 10-K for the fiscal year ended December 31, 2024, on June 2, 2025.
Is Onconetix, Inc. considered a well-known seasoned issuer?
No, Onconetix, Inc. is not a well-known seasoned issuer, as indicated by the unchecked box in its 10-K filing.
What was Onconetix, Inc.'s previous company name?
Onconetix, Inc. was formerly known as Blue Water Biotech, Inc., with a name change on April 24, 2023, and before that, Blue Water Vaccines Inc. on July 10, 2019.
Has Onconetix, Inc. filed all required reports with the SEC?
Yes, Onconetix, Inc. has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months.
What is Onconetix, Inc.'s business address?
Onconetix, Inc.'s business address is 201 E. Fifth Street, Suite 1900, Cincinnati, OH 45202.
What is the par value of Onconetix, Inc.'s common stock?
The par value of Onconetix, Inc.'s common stock is $0.00001.
Is Onconetix, Inc. an accelerated filer?
No, Onconetix, Inc. is a non-accelerated filer, as indicated in its 10-K filing.
What industry does Onconetix, Inc. operate in?
Onconetix, Inc. operates in the Pharmaceutical Preparations industry, classified under SIC code 2834.
Has Onconetix, Inc. submitted all required Interactive Data Files?
Yes, Onconetix, Inc. has submitted electronically every Interactive Data File required pursuant to Rule 405 of Regulation S-T during the preceding 12 months.
Industry Context
Onconetix, Inc. operates within the pharmaceutical preparations industry, a sector characterized by extensive research and development, stringent regulatory oversight, and significant competition. Companies in this space often focus on developing novel therapeutics, which can involve long development cycles and substantial capital investment. Key trends include advancements in biotechnology, personalized medicine, and the ongoing demand for innovative treatments for various diseases.
Regulatory Implications
As a non-accelerated filer and smaller reporting company, Onconetix is subject to specific SEC reporting requirements. While these classifications allow for scaled disclosures, the company must still adhere to all filing obligations under the Securities Exchange Act of 1934, including timely submission of reports and interactive data files. Non-compliance could lead to penalties and affect investor confidence.
What Investors Should Do
- Monitor future filings for financial performance details.
- Research the company's product pipeline and development stage.
- Assess the competitive landscape within its specific therapeutic areas.
Key Dates
- 2024-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K filing.
- 2025-06-02: 10-K Filing Date — Indicates the official submission date of the annual report to the SEC.
- 2023-04-24: Name Change from Blue Water Biotech, Inc. — Reflects a significant corporate identity change.
- 2019-07-10: Name Change from Blue Water Vaccines Inc. — Indicates a prior corporate identity change.
Glossary
- Non-accelerated filer
- A filer that does not meet the thresholds for accelerated or large accelerated filer status, generally indicating a smaller market capitalization. (Onconetix's classification as a non-accelerated filer suggests its size and reporting requirements are less stringent.)
- Smaller reporting company
- A company that meets certain criteria for revenue and public float, allowing for scaled disclosure requirements. (This classification, along with non-accelerated filer status, indicates Onconetix is subject to reduced SEC reporting obligations.)
- Par value
- The nominal or face value of a share of stock, often a very small amount for common stock. (Onconetix's common stock has a par value of $0.00001, which is a nominal amount and not indicative of market value.)
- Rule 405 of Regulation S-T
- Requires registrants to submit all Interactive Data Files electronically. (Onconetix's confirmation of submitting these files indicates compliance with electronic filing mandates.)
- SIC Code 2834
- Standard Industrial Classification code for Pharmaceutical Preparations. (This code categorizes Onconetix's primary business activity within the pharmaceutical industry.)
Year-Over-Year Comparison
This 10-K filing covers the fiscal year ended December 31, 2024. As specific financial metrics such as revenue, net income, and margins were not detailed in the provided excerpt, a direct comparison to the previous year's filing cannot be made. However, the filing confirms Onconetix's compliance with SEC reporting requirements for the preceding 12 months, indicating continued operational adherence.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on June 2, 2025 by 513-620-4101 regarding Onconetix, Inc. (ONCO).